3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)Fátima Cardoso, Eric P. Winer, Alessandra Gennari et al.|Annals of Oncology|2016Cited by 2.1k
Mutational Processes Molding the Genomes of 21 Breast CancersSerena Nik‐Zainal, Michael S. Neuberger, Ludmil B. Alexandrov et al.|Cell|2012Cited by 2k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Alan S. Coates, Andrew Tutt, Binghe Xu et al.|Annals of Oncology|2015Cited by 1.8k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialAndrew Tutt, James Carmichael, Mark E. Robson et al.|The Lancet|2010Cited by 1.6k
Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast CancerAndrew Tutt, Charles E. Geyer|New England Journal of Medicine|2021Cited by 1.6k